Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Focus of the Report: This report focuses on bioimpedance analysis (BIA) for diagnosis, predicting development, selection of treatment, and monitoring of lymphedema (LE).
Technology Description: BIA measures the differential impedance (resistance) to low level electrical current to eval…
Focus of the Report: This Health Technology Assessment focuses on the efficacy and safety of a monoclonal antibody, erenumab (Aimovig), for prevention of episodic or chronic migraine.
Technology Description: Erenumab is a human calcitonin gene–related peptide (CGRP) receptor monoclonal antibody that is produced using recombinant DNA technology in cell …
Dexamethasone is a glucocorticoid that is FDA-approved for numerous indications; it is under investigation for the treatment of COVID-19. Glucocorticoids are adrenocortical steroids that modify the body’s immune responses to diverse stimuli. Dexamethasone is indicated for treatment of allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hema…
Focus of the Report: This report evaluates the efficacy and safety of the gene replacement therapy onasemnogene abeparvovec-xioi (Zolgensma or AVXS-101) for treatment of patients with spinal muscular atrophy (SMA) type 1.
Technology Description: Onasemnogene abeparvovec is a single-dos…
Focus of the Report: This report compares the effectiveness and safety of skin substitutes (cellular and acellular) as an addition to standard wound care (SWC) with SWC alone and compared with the adjunct use of alternative skin substitute products to treat chronic or nonhealing venous leg ulcers in adults.
Ayvakit (avapritinib) is an oral potent and selective inhibitor of activated KIT and PDGFRA mutant kinases, particularly activation loop mutations and highly resistant PDGFRA D842V mutation. It is indicated for the treatment of adults with unresectable or metastatic gastrointestinal s…
Fenfluramine is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of seizures associated with Dravet syndrome in patients aged 2 years and older.
Givlaari is a subcutaneously administered ribonucleic acid interference (RNAi) agent that inhibits delta-aminolevulinate synthase 1 (ALAS1) synthesis, a key regulator of the heme biosynthetic pathway in the liver. Givlaari is believed to reduce ALAS1 levels, thereby decreasing delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Decreasing ALA and PBG levels to n…
Focus of the Report: This report evaluates the use of tisagenlecleucel (Kymriah) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) or r/r diffuse large B-cell lymphoma (DLBCL).
Technology Description: Tisagenlecleucel therapy is a form of chime…
If you have a Hayes login, click here to view the full report on the Knowledge Center.